{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:58:43Z","timestamp":1790657923144,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971329"],"award-info":[{"award-number":["31971329"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170564"],"award-info":[{"award-number":["32170564"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023A04J1257"],"award-info":[{"award-number":["2023A04J1257"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24051","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T04:11:22Z","timestamp":1704341482000},"page":"e24051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-1535","authenticated-orcid":false,"given":"Rong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e24051_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ijlh.12214","article-title":"Thrombocytopenia: an update","volume":"36","author":"Smock","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24051_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24051_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"9471","key":"10.1016\/j.heliyon.2024.e24051_bib4","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","article-title":"Aplastic anaemia","volume":"365","author":"Brodsky","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24051_bib5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24051_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1634\/theoncologist.1-6-371","article-title":"The problem of thrombocytopenia after hematopoietic stem cell transplantation","volume":"1","author":"Nash","year":"1996","journal-title":"Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3324\/haematol.2011.055830","article-title":"Immune thrombocytopenia in children and adults: what's the same, what's different?","volume":"96","author":"Schulze","year":"2011","journal-title":"Haematologica"},{"issue":"6481","key":"10.1016\/j.heliyon.2024.e24051_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/369568a0","article-title":"Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin","volume":"369","author":"Kaushansky","year":"1994","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24051_bib9","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24051_bib10","first-page":"813","article-title":"Advances on thrombopoietin receptor agonist in severe aplastic anemia","volume":"38","author":"Du","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib11","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24051_bib12","first-page":"482","article-title":"Romiplostim (Nplate), a treatment option for immune (idiopathic) thrombocytopenic purpura","volume":"34","author":"Hubulashvili","year":"2009","journal-title":"P T"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24051_bib13","first-page":"1171","article-title":"Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura","volume":"23","author":"Dmytrijuk","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24051_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40265-015-0525-4","article-title":"Lusutrombopag: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib15","first-page":"734","article-title":"Pharmaceutical approval update","volume":"43","author":"Kaufman","year":"2018","journal-title":"P T"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24051_bib16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","article-title":"Avatrombopag: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24051_bib17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e24051_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.680411","article-title":"Off-label use of thrombopoietin receptor agonists: case series and review of the literature","volume":"11","author":"Capecchi","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24051_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e24051_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.704093","article-title":"Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24051_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11192-006-0086-0","article-title":"On the origins of bibliometrics","volume":"68","author":"Godin","year":"2006","journal-title":"Scientometrics"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24051_bib22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.18692","article-title":"A bibliometric analysis of primary immune thrombocytopenia from 2011 to 2021","volume":"201","author":"Ou","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24051_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17075","article-title":"A scientometrics and visualization analysis of oxidative stress modulator Nrf2 in cancer profiles its characteristics and reveals its association with immune response","volume":"9","author":"Guo","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e24051_bib24","article-title":"Bibliometric analysis of the global research development of bone metastases in prostate cancer: a 22-year study","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24051_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: an R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetr"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24051_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib27","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24051_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24051_bib29","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"issue":"10004","key":"10.1016\/j.heliyon.2024.e24051_bib30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e24051_bib31","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1182\/bloodadvances.2020004110","article-title":"Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice","volume":"5","author":"Cheng","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.heliyon.2024.e24051_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fmed.2020.00066","article-title":"Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)","volume":"7","author":"Giordano","year":"2020","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24051_bib33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24051_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.18864","article-title":"Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: a real-world study in China","volume":"202","author":"Cheng","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e24051_bib35","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","article-title":"Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator","volume":"130","author":"Vlachodimitropoulou","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib36","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00277-022-04968-8","article-title":"Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study","volume":"101","author":"Yang","year":"2022","journal-title":"Ann. Hematol."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e24051_bib37","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24051_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/CEOR.S262772","article-title":"Cost- effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease","volume":"12","author":"Mladsi","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24051_bib41","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1007\/s12325-022-02235-w","article-title":"Systematic review with meta-analysis: efficacy and safety of lusutrombopag for severe thrombocytopenia in patients with chronic liver disease undergoing invasive procedures","volume":"39","author":"Orme","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.heliyon.2024.e24051_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24051_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-021-03153-3","article-title":"Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study","volume":"114","author":"Giammarco","year":"2021","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24051_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4274\/balkanmedj.galenos.2022.2022-2-48","article-title":"Eltrombopag for the treatment of poor graft function following haematopoietic cell transplantation: real-life data","volume":"40","author":"K\u0131rcal\u0131","year":"2023","journal-title":"Balkan Med. J."},{"key":"10.1016\/j.heliyon.2024.e24051_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221127532","article-title":"Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation","volume":"13","author":"Zhou","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.heliyon.2024.e24051_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1099372","article-title":"Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: a pilot study","volume":"11","author":"Ruan","year":"2023","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24051_bib47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ejh.13925","article-title":"Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Zheng","year":"2023","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24051_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"Peffault de Latour","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e24051_bib49","doi-asserted-by":"crossref","first-page":"12846","DOI":"10.1182\/blood-2022-155813","article-title":"Outcomes with eltrombopag for poor graft function following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"140","author":"Shahzad","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24051_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211011353","article-title":"Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report","volume":"12","author":"Gruden","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24051_bib51","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11239-021-02604-2","article-title":"Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia","volume":"53","author":"Maraziti","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.heliyon.2024.e24051_bib52","article-title":"Eltrombopag improves refractory thrombocytopenia in a patient with systemic lupus erythematosus","volume":"2018","author":"Shima","year":"2018","journal-title":"Case Rep Rheumatol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24051_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0973-6247.177204","article-title":"A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag","volume":"10","author":"Purushothaman","year":"2016","journal-title":"Asian J. Transfus. Sci."},{"key":"10.1016\/j.heliyon.2024.e24051_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211001139","article-title":"Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review","volume":"12","author":"Agarwal","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24051_bib55","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e24051_bib56","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2010-08-304725","article-title":"Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations","volume":"116","author":"Pecci","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26692","article-title":"Eltrombopag use in a patient with Wiskott-Aldrich syndrome","volume":"64","author":"Gabelli","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24051_bib58","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/09537104.2022.2096211","article-title":"Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure","volume":"33","author":"Arif","year":"2022","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24051_bib59","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24051_bib60","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3324\/haematol.2020.249995","article-title":"Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome","volume":"105","author":"Vicente","year":"2020","journal-title":"Haematologica"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:40:11Z","timestamp":1790656811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024000823"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24051","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24051"}}